Larvol Delta - Randomized-openlabel-phase-2-study-of-andecaliximab-plus-nivolumab-versus-nivolumab-alone-in-advanced-gastric-cancer-identifies-biomarkers-associated-with-survival

andecaliximab (GS-5745) - Gilead

Opdivo (nivolumab) - Ono Pharma, BMS

http://www.ncbi.nlm.nih.gov/pubmed/34893523

Mar 8, 2022

SHARE THIS

Print
Email
More sharing

Reddit

StumbleUpon

Delicious

Prev Next